Drawing for RYSETRX

USPTO serial 99660704

RYSETRX

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
MACFARLANE, JAMES W
Law office
TMEG LAW OFFICE 104

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with RYSETRX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael McGovern

Michael McGovern LZ Legal Services, LLC2828 N. Central Ave.PMB #1510Phoenix, AZ 85004

Goods and services

ClassDescriptionStatusFirst use
035On-line retail store services featuring hormone replacement therapy medications, peptide therapy medications, and personalized wellness medications, compounds and tablets; Subscription-based online retail store services in the field of hormone replacement therapy medications, peptide therapy medications, and personalized wellness medications, compounds and tabletsACTIVE—
044Medical consultations provided via phone, online chat or videoconferencing; Telemedicine services; Dermatology servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 9, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jun 9, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Jun 9, 2026CNSLSUSPENSION LETTER WRITTEN—
Jun 9, 2026DOCKASSIGNED TO EXAMINER—
Feb 19, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 19, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 19, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance